Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Biocon Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocon Biologics, Yoshindo Launch Ustekinumab Biosimilar in Japan
Details : Yesintek (ustekinumab) is a human interleukin-12 and -23 antagonist indicated for the treatment of adult patients plaque psoriasis and active psoriatic arthritis.
Product Name : Yesintek
Product Type : Antibody
Upfront Cash : Inapplicable
May 21, 2025
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Biocon Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan
Details : Ustekinumab, a biosimilar of Stelara, is a monoclonal antibody used to treat several autoimmune conditions and Denosumab, a biosimilar referencing Prolia®, is a monoclonal antibody for the treatment of osteoporosis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement